Relebactam

N/A

Report date: 2022/07/04 19:38:02
NMEQIDP

Base Information

Drug NameRelebactam
Drug Alias Namerelebactam瑞来巴坦relebactamumMK-7655
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionBeta Lactamase inhibitors
TargetsBeta Lactamase
Therapy Area/IndicationsPyelonephritisUrinary Tract InfectionsIntraabdominal Infections +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsPyelonephritisUrinary Tract InfectionsIntraabdominal Infections +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG